Personalized Medicine Powered By AI and Patient RNA

Rare disorder patients are disproportionately impacted by the lack of effective treatments. Unravel developed a personalized medicine approach using self-collected RNA to drive rapid drug repurposing as a way to clinically test entirely new drug targets.

• The use of RNA transcriptomics as a fundamental data source for understanding dynamic human biology.
• The impact of applying practical, self-collected nasal swabs for large-scale and longitudinal molecular clinical data collection to build Living Molecular Twins^™.
• The novel concept of applying rapid prototyping to drug development, using clinical translation of AI-predicted repurposed drugs as clinical tools to validate discovered drug targets.

Unravel catalyzes the discovery of effective treatments for rare disease patients by building Living Molecular Twins^™ for individual patients to enable personalized medicine. This process discovers shared mechanisms across many disorders that are rapidly tested in real patients using repurposed drugs, defragmenting rare disorders and improving patient outcomes.